There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Yan Li |
| Institution: | Washington University in St. Louis |
| Department: | Department of Neurology |
| Country: | |
| Proposed Analysis: | We would like to request all the plasma Aβ data from FNIH plasma Aβ assay validation Study 1 dataset that was uploaded to LONI recently (in May) and all the related demographics, cognitive/clinical, biomarker, imaging biomarker data. The FNIH plasma Aβ assay validation Study 1 included plasma Aβ measured by six centers, Ours (WashU, Dr. Bateman's lab) is one of the centers. The following analyses will be performed: 1. AUCs of plasma Aβ42/Aβ40 itself and with other biological variable (e.g. age, APOE, sex) in classifying amyloid PET status. 2. Correlations in plasma Aβ42, Aβ40, Aβ42/Aβ40 measured by all assays, and if low correlation, exam the possible cause. Correlations between Aβ42/Aβ40 and other clinical/cognitive outcomes, biomarkers (CSF and plasma tau, pTau, NfL, etc). 3. Evaluate the percentage agreement and disagreement in the plasma Aβ42/Aβ40 status (positive, negative). Assess whether there is a pattern to miss categorization by type of assay (mass spec vs immunoassay), type of participants (cognitive status, age, APOE ε4 status, other fluid and imaging biomarker status, etc.) 4. Compare the %CV of each assay and exam whether the %CV or the difference in ratio is the major factor that influence the performance of the assay in terms of classifying amyloid PET status. |
| Additional Investigators |
